

RECEIVED
CENTRAL FAX CENTER
APR 29 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF FACSIMILE

MAIL STOP PETITION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being facsimile transmitted to facsimile number 571-273-8300 on the date shown below.

Attorney or Agent
For Applicant(s)

Reg: 1201, 7C, 857

Date Transmitted

December 04, 2009

PETITION UNDER 37 C.F.R. § 1.59(b) TO EXPUNGE ASSIGNMENT RECORDS
(M.P.E.P. § 323.01(d), 8th Ed.)

1. Rigel Pharmaceuticals, Inc. ("Rigel") is the Assignee of the applications listed below.
2. Gregg Benson is authorized to act on behalf of Pfizer Inc. ("Pfizer").
3. Pfizer hereby petitions under 37 C.F.R. § 1.59(b) to expunge the assignment records concerning the Confirmation of Exclusive Patent License ("Confirmation") that was recorded on August 15, 2005, at Reel 016888, Frames 0112-0115, against the following applications:
 - a) 10/355,543
 - b) 10/858,343
 - c) 10/911,684
 - d) PCT/US03/03022
 - e) 10/631,029
 - f) PCT/US2003/024087
 - g) PCT/US04/24716
 - h) 10/903,263
 - i) 60/590,789
4. The Confirmation concerned a Collaborative Research and License Agreement ("Agreement"), dated January 18, 2005, between Rigel and its licensee, Pfizer. The Confirmation unintentionally contained erroneous information, was unintentionally recorded in error against the listed patent applications, and both Rigel and Pfizer agree that the Confirmation was recorded unnecessarily and should be expunged.
5. The normal corrective procedures outlined in MPEP § 323.01(a) through § 323.01(c) would not provide Rigel and Pfizer adequate relief because 1) the errors in the recorded Confirmation are not mere typographical errors, and 2) the Confirmation was recorded in error against the listed patent applications.
6. Rigel and Pfizer assert the integrity of the assignment records would not be affected by granting this Petition because recording the Confirmation was unnecessary. Moreover,

09/23/2010 CKHLOK

01 FC:1462

400.00 DA

Adjustment Date: 09/23/2010

04/30/2010 JVUNG1

01 FC:1463

200.00 CR

Page 1 of 2

CKHLOK

161445 10631029

RECEIVED
CENTRAL FAX CENTER

APR 29 2010

failure to grant this Petition would result in maintaining erroneous property rights records for the listed patent applications.

7. Please address all future correspondence concerning this Petition to Customer Number 74839: Travis Young, Ph.D. at Rigel Pharmaceuticals, Inc., 1180 Veterans Blvd., South San Francisco, CA, 94080, telephone number (650) 624-1434.


8. Fee
The fee required by 37 C.F.R. § 1.17(g) is submitted herewith by deposit authority:

- ☒ Charge Deposit Account No. 16-1445 the sum of \$200.00.
- ☒ The Director is hereby authorized to charge any additional fee(s) required to file this Petition, or credit over-payment, to Deposit Account No. 16-1445.

Respectfully submitted,

PFIZER INC.

By


Gregg C. Benson
Assistant General Counsel
Registration No. 30,997